<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36937488</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1844-3117</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of medicine and life</Title><ISOAbbreviation>J Med Life</ISOAbbreviation></Journal><ArticleTitle>Post-COVID-19 syndrome: Insights into a novel post-infectious systemic disorder.</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>202</EndPage><MedlinePgn>195-202</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.25122/jml-2022-0329</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) is currently considered a complex systemic infectious and inflammatory disease, determined by the infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and the cause of one of the most important epidemiological phenomena in the last century - the COVID-19 pandemic. This infectious-inflammatory disease may generate a wide range of clinical manifestations and biological modifications, explained by the ubiquitous nature of the SARS-CoV-2 receptors, represented by the angiotensin-converting enzyme-2 (ACE-2), and by the host's violent immune and proinflammatory reaction to the viral infection. These manifestations include immunological disturbances, which, according to certain clinical findings, may persist post-infection, in the form of a presumed systemic inflammatory entity, defined by several clinical concepts with a common pathological significance: post-COVID-19 multisystem (or systemic) inflammatory syndrome, post-COVID syndrome or long-COVID. Although the pathophysiological mechanisms of the post-COVID-19 syndrome are elusive at the present moment, there are currently several studies that describe a systemic inflammatory or autoimmune phenomenon following the remission of the COVID-19 infection in some patients, which suggests the existence of molecular and cellular immune abnormalities, most probably due to the host's initial violent immune response to the viral infection, in the form of three overlapping entities: secondary hemophagocytic lymph histiocytosis (HLH), macrophage activation syndrome (MAS) and cytokine release syndrome (CRS). Thus, this is reminiscent of different classic autoimmune diseases, in which various infections are risk factors in developing the autoimmune process.</AbstractText><CopyrightInformation>&#xa9;2023 JOURNAL of MEDICINE and LIFE.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stoian</LastName><ForeName>Marilena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dr. Ion Cantacuzino Clinical Hospital, Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Procopiescu</LastName><ForeName>Bianca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dr. Ion Cantacuzino Clinical Hospital, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x218;eitan</LastName><ForeName>Silviu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dr. Ion Cantacuzino Clinical Hospital, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarlat</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dr. Ion Cantacuzino Clinical Hospital, Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Romania</Country><MedlineTA>J Med Life</MedlineTA><NlmUniqueID>101477617</NlmUniqueID><ISSNLinking>1844-122X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">immune system</Keyword><Keyword MajorTopicYN="N">post-COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">systemic inflammatory syndrome</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>20</Day><Hour>4</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36937488</ArticleId><ArticleId IdType="pmc">PMC10015558</ArticleId><ArticleId IdType="doi">10.25122/jml-2022-0329</ArticleId><ArticleId IdType="pii">JMedLife-16-195</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scarlat G, Dona B, Procopiescu B, Stoian M. Post-Covid-19 Immunological Disorder: A Possible Pathological Entity in a 43 Year Old Man. Internal Medicine. 2022;19(2):77&#x2013;94. doi: 10.2478/inmed-2022-0210.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/inmed-2022-0210</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris SB, Schwartz NG, Patel P, Abbo L, et al. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection&#x2013;United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1450&#x2013;1456. doi: 10.15585/mmwr.mm6940e1externalicon.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6940e1externalicon</ArticleId><ArticleId IdType="pmc">PMC7561225</ArticleId><ArticleId IdType="pubmed">33031361</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19: long term effects.  Available from:  https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-long-term-effects/art-20490351.</Citation></Reference><Reference><Citation>Anaya JM, Herr&#xe1;n M, Beltr&#xe1;n S, Rojas M. Is post-COVID syndrome an autoimmune disease? Expert Rev Clin Immunol. 2022 Jul;18(7):653&#x2013;666. doi: 10.1080/1744666X.2022.2085561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2022.2085561</ArticleId><ArticleId IdType="pubmed">35658801</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M, Rodr&#xed;guez Y, Acosta-Ampudia Y, Monsalve DM, et al. Autoimmunity is a hallmark of post-COVID syndrome. J Transl Med. 2022 Mar 16;20(1):129. doi: 10.1186/s12967-022-03328-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03328-4</ArticleId><ArticleId IdType="pmc">PMC8924736</ArticleId><ArticleId IdType="pubmed">35296346</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodr&#xed;guez Y, et al. Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome. J Infect Dis. 2022 Jun 15;225(12):2155&#x2013;2162. doi: 10.1093/infdis/jiac017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020 Dec 3;383(23):2255&#x2013;2273. doi: 10.1056/NEJMra2026131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros&#xe1;rio C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013 Aug 22;11:185. doi: 10.1186/1741-7015-11-185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-185</ArticleId><ArticleId IdType="pmc">PMC3751883</ArticleId><ArticleId IdType="pubmed">23968282</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoenfeld Y. Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev. 2020 Jun;19(6):102538. doi: 10.1016/j.autrev.2020.102538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102538</ArticleId><ArticleId IdType="pmc">PMC7131471</ArticleId><ArticleId IdType="pubmed">32268212</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar B, Aleem S, Saleh H, Petts J, Ballas ZK. A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults. J Clin Immunol. 2017 Oct;37(7):638&#x2013;643. doi: 10.1007/s10875-017-0439-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-017-0439-x</ArticleId><ArticleId IdType="pubmed">28871523</ArticleId></ArticleIdList></Reference><Reference><Citation>Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol. 2013 Jun;161(5):609&#x2013;22. doi: 10.1111/bjh.12293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.12293</ArticleId><ArticleId IdType="pubmed">23577835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DW, Gardner R, Porter DL, Louis CU, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188&#x2013;95. doi: 10.1182/blood-2014-05-552729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-05-552729</ArticleId><ArticleId IdType="pmc">PMC4093680</ArticleId><ArticleId IdType="pubmed">24876563</ArticleId></ArticleIdList></Reference><Reference><Citation>Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125:2908&#x2013;14. doi: 10.1182/blood-2015-01-551622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-01-551622</ArticleId><ArticleId IdType="pubmed">25758828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Casals M, Brito-Zer&#xf3;n P, L&#xf3;pez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014 Apr 26;383(9927):1503&#x2013;1516. doi: 10.1016/S0140-6736(13)61048-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61048-X</ArticleId><ArticleId IdType="pubmed">24290661</ArticleId></ArticleIdList></Reference><Reference><Citation>Rekha TS, Kiran HS, Nandini NM, Murthy S. Cytology of secondary hemophagocytic lymphohistiocytosis masquerading as lymphoma in a nonimmunocompromised adult. J Cytol. 2014 Oct-Dec;31(4):239&#x2013;41. doi: 10.4103/0970-9371.151146.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0970-9371.151146</ArticleId><ArticleId IdType="pmc">PMC4349024</ArticleId><ArticleId IdType="pubmed">25745299</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieni E, Cetica V, Piccin A, Gherlinzoni F, et al. Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series. PLoS One. 2012;7(9):e44649. doi: 10.1371/journal.pone.0044649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044649</ArticleId><ArticleId IdType="pmc">PMC3436758</ArticleId><ArticleId IdType="pubmed">22970278</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodi A, Dav&#xec; S, Pringe AB, Pistorio A, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009 Nov;60(11):3388&#x2013;99. doi: 10.1002/art.24883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24883</ArticleId><ArticleId IdType="pubmed">19877067</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortis E, Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl. 2006 Jul;95(452):38&#x2013;41. doi: 10.1080/08035320600649713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08035320600649713</ArticleId><ArticleId IdType="pubmed">16801165</ArticleId></ArticleIdList></Reference><Reference><Citation>Celkan T, Berrak S, Kazanci E, Ozy&#xfc;rek E, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: a multicenter study from Turkey. Turk J Pediatr. 2009 May-Jun;51(3):207&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">19817262</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelesidis T, Humphries R, Terashita D, Eshaghian S, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Los Angeles County. J Med Virol. 2012 May;84(5):777&#x2013;85. doi: 10.1002/jmv.23267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23267</ArticleId><ArticleId IdType="pmc">PMC8067666</ArticleId><ArticleId IdType="pubmed">22431026</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan C, Li C, Ma H, Li Y, Zhang H. Immunopathogenesis of Coronavirus-Induced Acute Respiratory Distress Syndrome (ARDS): Potential Infection-Associated Hemophagocytic Lymphohistiocytosis. Clin Microbiol Rev. 2020 Oct 14;34(1):e00074&#x2013;20. doi: 10.1128/CMR.00074-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00074-20</ArticleId><ArticleId IdType="pmc">PMC7566897</ArticleId><ArticleId IdType="pubmed">33055229</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracaglia C, Prencipe G, De Benedetti F. Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. Pediatr Rheumatol Online J. 2017 Jan 17;15(1):5. doi: 10.1186/s12969-016-0130-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-016-0130-4</ArticleId><ArticleId IdType="pmc">PMC5240371</ArticleId><ArticleId IdType="pubmed">28095869</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Chen X, Cai Y, Xia J, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934&#x2013;943. doi: 10.1001/jamainternmed.2020.0994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.0994</ArticleId><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020 Jun;19(6):102537. doi: 10.1016/j.autrev.2020.102537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102537</ArticleId><ArticleId IdType="pmc">PMC7195002</ArticleId><ArticleId IdType="pubmed">32251717</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xfa;&#xf1;ez-Torr&#xf3;n C, Ferrer-G&#xf3;mez A, Moreno Moreno E, P&#xe9;rez-Mies B, et al. Secondary haemophagocytic lymphohistiocytosis in COVID-19: correlation of the autopsy findings of bone marrow haemophagocytosis with HScore. J Clin Pathol. 2022 Jun;75(6):383&#x2013;389. doi: 10.1136/jclinpath-2020-207337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jclinpath-2020-207337</ArticleId><ArticleId IdType="pubmed">33722841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergsten E, Horne A, Aric&#xf3; M, Astigarraga I, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017 Dec 21;130(25):2728&#x2013;2738. doi: 10.1182/blood-2017-06-788349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-06-788349</ArticleId><ArticleId IdType="pmc">PMC5785801</ArticleId><ArticleId IdType="pubmed">28935695</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima R, Filho CC, Filho CMF, Vaisman M, et al. Hemophagocytic syndrome and COVID-19. Respiratory Medicine Case Reports. 2020;31:2213&#x2013;0071. doi: 10.1016/j.rmcr.2020.101162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmcr.2020.101162</ArticleId><ArticleId IdType="pmc">PMC7347481</ArticleId><ArticleId IdType="pubmed">32704472</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalita P, Laishram D, Dey B, Mishra J, et al. Secondary Hemophagocytic Lymphohistiocytosis in Post-COVID-19 Patients: A Report of Two Cases. Cureus. 2021 Aug 20;13(8):e17328. doi: 10.7759/cureus.17328.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.17328</ArticleId><ArticleId IdType="pmc">PMC8450015</ArticleId><ArticleId IdType="pubmed">34557370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Han T, Chen J, Hou C, et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clin Transl Sci. 2020 Nov;13(6):1077&#x2013;1086. doi: 10.1111/cts.12805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12805</ArticleId><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, Tzioufas AG. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020 Dec;79(12):1661&#x2013;1663. doi: 10.1136/annrheumdis-2020-218009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218009</ArticleId><ArticleId IdType="pubmed">32581086</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomhof G, Mutsaers PGNJ, Leebeek FWG, Te Boekhorst PAW, et al. COVID-19-associated immune thrombocytopenia. Br J Haematol. 2020 Jul;190(2):e61&#x2013;e64. doi: 10.1111/bjh.16850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16850</ArticleId><ArticleId IdType="pmc">PMC7276755</ArticleId><ArticleId IdType="pubmed">32420612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zulfiqar AA, Lorenzo-Villalba N, Hassler P, Andr&#xe8;s E. Immune Thrombocytopenic Purpura in a Patient with Covid-19. N Engl J Med. 2020 Apr 30;382(18):e43. doi: 10.1056/NEJMc2010472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2010472</ArticleId><ArticleId IdType="pmc">PMC7179995</ArticleId><ArticleId IdType="pubmed">32294340</ArticleId></ArticleIdList></Reference><Reference><Citation>Angileri F, L&#xe9;gar&#xe9; S, Marino Gammazza A, Conway de Macario E, et al. Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19? Br J Haematol. 2020 Jul;190(2):e92&#x2013;e93. doi: 10.1111/bjh.16883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16883</ArticleId><ArticleId IdType="pmc">PMC7283741</ArticleId><ArticleId IdType="pubmed">32453861</ArticleId></ArticleIdList></Reference><Reference><Citation>Angileri F, Legare S, Marino Gammazza A, Conway de Macario E, et al. Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun Rev. 2020 Aug;19(8):102591. doi: 10.1016/j.autrev.2020.102591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102591</ArticleId><ArticleId IdType="pmc">PMC7289093</ArticleId><ArticleId IdType="pubmed">32535095</ArticleId></ArticleIdList></Reference><Reference><Citation>Moody R, Wilson K, Flanagan KL, Jaworowski A, Plebanski M. Adaptive Immunity and the Risk of Autoreactivity in COVID-19. Int. J. Mol. Sci. 2021;22:8965. doi: 10.3390/ijms22168965.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168965</ArticleId><ArticleId IdType="pmc">PMC8396528</ArticleId><ArticleId IdType="pubmed">34445670</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID Symptom Study  How Long Does COVID-19 Last?  Available from:  https://covid19.joinzoe.com/post/covid-long-term?fbclid=IwAR1RxIcmmdL-EFjh_aI-</Citation></Reference><Reference><Citation>Bektas A, Schurman SH, Franceschi C, Ferrucci L. A public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short-and long-term inflammaging? Immun Ageing. 2020 Aug 24;17:23. doi: 10.1186/s12979-020-00196-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-020-00196-8</ArticleId><ArticleId IdType="pmc">PMC7443812</ArticleId><ArticleId IdType="pubmed">32849908</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux J, Dotan A, Fritzler MJ, Bogdanos DP, et al. Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmun Rev. 2022 Mar;21(3):103012. doi: 10.1016/j.autrev.2021.103012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.103012</ArticleId><ArticleId IdType="pmc">PMC8656211</ArticleId><ArticleId IdType="pubmed">34896650</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A, Vojdani E, Kharrazian D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. Front Immunol. 2021 Jan 19;11:617089. doi: 10.3389/fimmu.2020.617089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.617089</ArticleId><ArticleId IdType="pmc">PMC7873987</ArticleId><ArticleId IdType="pubmed">33584709</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, Apostolidis SA, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12:5417. doi: 10.1038/s41467-021-25509-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, Day Y, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283&#x2013;288. doi: 10.1038/s41586-021-03631-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Caricchio R, Casanova JL, Combes AJ, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021 Dec 15;131(24):e154886. doi: 10.1172/JCI154886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI154886</ArticleId><ArticleId IdType="pmc">PMC8670833</ArticleId><ArticleId IdType="pubmed">34710063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ca&#xf1;as CA. The triggering of post-COVID-19 autoimmunity phenomenon could be associated with both transient immunosupression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypotheses. 2020 Dec;145:110345. doi: 10.1016/j.mehy.2020.110345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110345</ArticleId><ArticleId IdType="pmc">PMC7556280</ArticleId><ArticleId IdType="pubmed">33080459</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao B, Wang C, Tan Y, Chen X, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) Front Immunol. 2020 May 1;11:827. doi: 10.3389/fimmu.2020.00827.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00827</ArticleId><ArticleId IdType="pmc">PMC7205903</ArticleId><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros&#xe1;rio C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013 Aug 22;11:185. doi: 10.1186/1741-7015-11-185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-185</ArticleId><ArticleId IdType="pmc">PMC3751883</ArticleId><ArticleId IdType="pubmed">23968282</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabeen R, Kaplan MH. The symphony of the ninth: the development and function of Th9 cells. Curr Opin Immunol. 2012 Jun;24(3):303&#x2013;7. doi: 10.1016/j.coi.2012.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2012.02.001</ArticleId><ArticleId IdType="pmc">PMC3368035</ArticleId><ArticleId IdType="pubmed">22365614</ArticleId></ArticleIdList></Reference><Reference><Citation>Orologas-Stavrou N, Politou M, Rousakis P, Kostopoulos IV, et al. Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses. 2020 Dec 25;13(1):26. doi: 10.3390/v13010026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010026</ArticleId><ArticleId IdType="pmc">PMC7824046</ArticleId><ArticleId IdType="pubmed">33375675</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal R. COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications. Endocrine. 2020;68:251&#x2013;252. doi: 10.1007/s12020-020-02325-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-020-02325-1</ArticleId><ArticleId IdType="pmc">PMC7186765</ArticleId><ArticleId IdType="pubmed">32346813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheatland R. Molecular mimicry of ACTH in SARS-implications for corticosteroid treatment and prophylaxis. Med Hypotheses. 2004;63(5):855&#x2013;62. doi: 10.1016/j.mehy.2004.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2004.04.009</ArticleId><ArticleId IdType="pmc">PMC7126000</ArticleId><ArticleId IdType="pubmed">15488660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y, He L, Zhang Q, Huang Z, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004 Jun;203(2):622&#x2013;30. doi: 10.1002/path.1560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1560</ArticleId><ArticleId IdType="pmc">PMC7167761</ArticleId><ArticleId IdType="pubmed">15141376</ArticleId></ArticleIdList></Reference><Reference><Citation>Freire Santana M, Borba MGS, Ba&#xed;a-da-Silva DC, Val F, et al. Case report: adrenal pathology findings in severe COVID-19: an autopsy study. Am J Trop Med Hygiene. 2020;103(4):1604&#x2013;7. doi: 10.4269/ajtmh.20-0787.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-0787</ArticleId><ArticleId IdType="pmc">PMC7543860</ArticleId><ArticleId IdType="pubmed">32876012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley B, Naresh KN, Roufosse C, Nicholson AG, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020;1(6):e245&#x2013;53. doi: 10.1016/S2666-5247(20)30115-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30115-4</ArticleId><ArticleId IdType="pmc">PMC7440861</ArticleId><ArticleId IdType="pubmed">32844161</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharrack N, Baxter CT, Paddock M, Uchegbu E. Adrenal haemorrhage as a complication of COVID-19 infection. BMJ Case Reports CP. 2020;13(11):e239643. doi: 10.1136/bcr-2020-239643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-239643</ArticleId><ArticleId IdType="pmc">PMC7705581</ArticleId><ArticleId IdType="pubmed">33257399</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankel M, Feldman I, Levine M, Frank Y, Bogot NR, Benjaminov O, et al. Bilateral adrenal hemorrhage in coronavirus disease 2019 patient: a case report. J Clin Endocrinol Metabol. 2020;105(12):3745&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454653</ArticleId><ArticleId IdType="pubmed">32738040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Guruparan T, Siddiqi S, Sheth R, et al. A case of adrenal infarction in a patient with COVID 19 infection. BJR| case reports. 2020;6(3):20200075. doi: 10.1259/bjrcr.20200075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1259/bjrcr.20200075</ArticleId><ArticleId IdType="pmc">PMC7465735</ArticleId><ArticleId IdType="pubmed">32922854</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa BA, da Luz KV, Campos SEV, Lopes GS, et al. Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature. Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):26&#x2013;31. doi: 10.1016/j.htct.2021.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.htct.2021.11.015</ArticleId><ArticleId IdType="pmc">PMC8768508</ArticleId><ArticleId IdType="pubmed">35075445</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivellese F, Prediletto E. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia. Autoimmun Rev. 2020 Jun;19(6):102536. doi: 10.1016/j.autrev.2020.102536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102536</ArticleId><ArticleId IdType="pmc">PMC7195011</ArticleId><ArticleId IdType="pubmed">32251718</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. 2020 Jul;92(7):726&#x2013;730. doi: 10.1002/jmv.25785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25785</ArticleId><ArticleId IdType="pmc">PMC7317908</ArticleId><ArticleId IdType="pubmed">32221983</ArticleId></ArticleIdList></Reference><Reference><Citation>Haznedaroglu IC, Malkan UY. Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies. Eur Rev Med Pharmacol Sci. 2016 Oct;20(19):4089&#x2013;4111.</Citation><ArticleIdList><ArticleId IdType="pubmed">27775788</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyazit Y, Aksu S, Haznedaroglu IC, Kekilli M, et al. Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. J Natl Med Assoc. 2007;99(1):57&#x2013;63. doi: 10.1182/blood.V106.11.4567.4567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V106.11.4567.4567</ArticleId><ArticleId IdType="pmc">PMC2569610</ArticleId><ArticleId IdType="pubmed">17304969</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers KE, Xiong S, Steer R, diZerega GS. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. 2000;18(4):287&#x2013;94. doi: 10.1634/stemcells.18-4-287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/stemcells.18-4-287</ArticleId><ArticleId IdType="pubmed">10924095</ArticleId></ArticleIdList></Reference><Reference><Citation>De la Iglesia I&#xf1;igo S, L&#xf3;pez-Jorge CE, G&#xf3;mez-Casares MT, Lemes Castellano A, et al. Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: a new role in the treatment of leukaemia for these agents. Leuk Res. 2009 Jun;33(6):810&#x2013;6. doi: 10.1016/j.leukres.2008.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2008.09.029</ArticleId><ArticleId IdType="pubmed">19010543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozako T, Soeda S, Yoshimitsu M, Arima N, et al. Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell leukemia cells. FEBS Open Bio. 2016 Apr 13;6(5):442&#x2013;60. doi: 10.1002/2211-5463.12055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2211-5463.12055</ArticleId><ArticleId IdType="pmc">PMC4856423</ArticleId><ArticleId IdType="pubmed">27419050</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-term effects of coronavirus (long COVID)  Available from:  https://www.nhs.uk/conditions/coronavirus-covid-19/long-term-effects-of-coronavirus-long-covid/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>